ABCL
Price
$3.27
Change
-$0.25 (-7.10%)
Updated
Feb 4, 04:59 PM (EDT)
Capitalization
1.05B
20 days until earnings call
Intraday BUY SELL Signals
CSPHF
Price
$1.00
Change
+$0.14 (+16.28%)
Updated
Sep 23 closing price
Capitalization
987.66M
Intraday BUY SELL Signals
Interact to see
Advertisement

ABCL vs CSPHF

Header iconABCL vs CSPHF Comparison
Open Charts ABCL vs CSPHFBanner chart's image
AbCellera Biologics
Price$3.27
Change-$0.25 (-7.10%)
Volume$49.61K
Capitalization1.05B
CSTONE PHARMACEUTICALS
Price$1.00
Change+$0.14 (+16.28%)
Volume$150
Capitalization987.66M
ABCL vs CSPHF Comparison Chart in %
View a ticker or compare two or three
VS
ABCL vs. CSPHF commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABCL is a Hold and CSPHF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (ABCL: $3.52 vs. CSPHF: $0.72)
Brand notoriety: ABCL and CSPHF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABCL: 116% vs. CSPHF: 600%
Market capitalization -- ABCL: $1.05B vs. CSPHF: $987.66M
ABCL [@Biotechnology] is valued at $1.05B. CSPHF’s [@Biotechnology] market capitalization is $987.66M. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABCL’s FA Score shows that 0 FA rating(s) are green whileCSPHF’s FA Score has 0 green FA rating(s).

  • ABCL’s FA Score: 0 green, 5 red.
  • CSPHF’s FA Score: 0 green, 5 red.
According to our system of comparison, ABCL is a better buy in the long-term than CSPHF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABCL’s TA Score shows that 5 TA indicator(s) are bullish while CSPHF’s TA Score has 2 bullish TA indicator(s).

  • ABCL’s TA Score: 5 bullish, 6 bearish.
  • CSPHF’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, both ABCL and CSPHF are a bad buy in the short-term.

Price Growth

ABCL (@Biotechnology) experienced а -11.78% price change this week, while CSPHF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.56%. For the same industry, the average monthly price growth was +1.40%, and the average quarterly price growth was +33.10%.

Reported Earning Dates

ABCL is expected to report earnings on Feb 24, 2026.

Industries' Descriptions

@Biotechnology (-2.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABCL($1.05B) has a higher market cap than CSPHF($988M). ABCL YTD gains are higher at: 2.924 vs. CSPHF (-19.474).
ABCLCSPHFABCL / CSPHF
Capitalization1.05B988M107%
EBITDA-212.36MN/A-
Gain YTD2.924-19.474-15%
P/E RatioN/AN/A-
Revenue35.3MN/A-
Total Cash496MN/A-
Total Debt142MN/A-
TECHNICAL ANALYSIS
Technical Analysis
ABCLCSPHF
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
38%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
48%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
37%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
31%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
30%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
28%
Advances
ODDS (%)
Bullish Trend 14 days ago
77%
N/A
Declines
ODDS (%)
Bearish Trend 3 days ago
84%
N/A
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ABCL
Daily Signal:
Gain/Loss:
CSPHF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CSMIX46.420.30
+0.65%
Columbia Small Cap Value Discv A
HSMTX13.830.01
+0.07%
Hartford Small Cap Value R5
NBGAX54.67-0.29
-0.53%
Neuberger Genesis Adv
PLIEX31.95-0.56
-1.72%
Plumb Equity Institutional
WVALX41.50-1.13
-2.65%
Weitz Large Cap Equity-Investor Cl

ABCL and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABCL has been loosely correlated with RXRX. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ABCL jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABCL
1D Price
Change %
ABCL100%
+0.57%
RXRX - ABCL
58%
Loosely correlated
-1.91%
CRSP - ABCL
57%
Loosely correlated
+1.34%
VCYT - ABCL
56%
Loosely correlated
-1.10%
ABSI - ABCL
55%
Loosely correlated
+2.32%
NTLA - ABCL
51%
Loosely correlated
-0.08%
More

CSPHF and

Correlation & Price change

A.I.dvisor tells us that CSPHF and BCAB have been poorly correlated (+9% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CSPHF and BCAB's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CSPHF
1D Price
Change %
CSPHF100%
N/A
BCAB - CSPHF
9%
Poorly correlated
+9.06%
SIGY - CSPHF
8%
Poorly correlated
+21.95%
NBTX - CSPHF
7%
Poorly correlated
+0.33%
HYFT - CSPHF
5%
Poorly correlated
-3.09%
ABCL - CSPHF
3%
Poorly correlated
+0.57%
More